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HCV monoinfection and HIV/HCV
coinfection enhance T-cell immune
senescence in injecting drug users early
during infection
Bart P. X. Grady1,2, Nening M. Nanlohy3 and Debbie van Baarle3,4,5*
Abstract
Background: Injecting drug users (IDU) are at premature risk of developing multimorbidity and mortality from
causes commonly observed in the elderly. Ageing of the immune system (immune-senescence) can lead to
premature morbidity and mortality and can be accelerated by chronic viral infections. Here we investigated the
impact of HCV monoinfection and HIV/HCV coinfection on immune parameters in (ex-) IDU. We analyzed telomere
length and expression of activation, differentiation and exhaustion markers on T cells at baseline (t = 1) and at
follow-up (t = 2) (median interval 16.9 years) in IDU who were: HCV mono-infected (n = 21); HIV/HCV coinfected
(n = 23) or multiple exposed but uninfected (MEU) (n = 8).
Results: The median time interval between t = 1 and t = 2 was 16.9 years. Telomere length within CD4+ and CD8+ T
cells decreased significantly over time in all IDU groups (p≤ 0.012). CD4+ T-cell telomere length in HCV mono-infected
IDU was significantly reduced compared to healthy donors at t = 1 (p < 0.008). HIV/HCV coinfected IDU had reduced
CD4+ and CD8+ T-cell telomere lengths (p≤ 0.002) to healthy donors i at t = 1. This was related to persistent levels of
immune activation but not due to increased differentiation of T cells over time. Telomere length decrease was
observed within all T-cell subsets, but mainly found in immature T cells (CD27+CD57+) (p≤ 0.015).
Conclusions: HCV mono-infection and HIV/HCV coinfection enhance T-cell immune-senescence. Our data suggest that
this occurred early during infection, which warrants early treatment for both HCV and HIV to reduce immune
senescence in later life.
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Background
As people age, the immune system exhibits age-
associated changes resulting in impaired immunity.
This so-called immune senescence is a complex multi-
factorial phenomenon characterized by a number of
features including: i) reduced number of naïve T cells;
ii) increased frequencies of differentiated CD28-CD57+
T cells that have a reduced proliferative capacity; iii)
reduced CD4/CD8 ratio; oligoclonal expansion of CD8
T cells, and iv) progressive shortening of telomeres
[1–3]. Telomeres are repetitive (TTAGGG)n nucleo-
tide sequences that shorten with each cell division [4].
Among people aged over 60 years, short leukocyte
telomere length has been associated with higher
mortality rates from infectious diseases [5].
People who inject drugs (injecting drug users, IDU)
are at increased risk of contracting both acute and
chronic infections [6, 7]. The prevalence of HCV
antibodies in IDU ranges from 15–98 % [8, 9]. Upon
HCV infection, 75 % of individuals progress to chronic
infection and are at risk for progressive liver disease,
liver cirrhosis and hepatocellular carcinoma [10]. The
worldwide prevalence of HIV infection among IDU is
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estimated to be 18 % [11]. With the advent of combination
antiretroviral therapy (cART) and decline in drug-related
causes of death, the mean age of IDU is increasing [12, 13]
and IDU are at premature risk of developing multimorbid-
ity and mortality from causes commonly observed in the
elderly [14, 15].
Immunological changes and increased levels of inflam-
mation could form the basis of this premature burden of
morbidity and mortality among ageing DU. Progression of
immune senescence was shown to be accelerated by
chronic viral infections such as HIV through (long-term)
continuous immune activation [16, 17]. Despite adequate
combination antiretroviral therapy (cART), HIV infected
individuals have increased risk for non-AIDS morbidity as
compared to age-matched controls [18, 19]. There is a
growing body of literature that suggests that HCV has a
role in extrahepatic morbidity and mortality likely through
a similar mechanism of immune activation [20, 21].
Indeed, like HIV, HCV infection also leads to PD-1high
and TIM-3high T cells, a phenotype associated with
exhaustion due to persistent antigenic pressure [22]. In
addition to HIV and HCV monoinfection, HIV/HCV
coinfected individuals do not only seem to have increased
risk for liver disease progression [23] but also progression
to AIDS [24], which suggests that both viruses could
enhance each other’s disease progression [25].
To assess the impact of an infection with HCV and
HIV/HCV specifically, we studied parameters associated
with immune senescence. To this end, we included IDU
with HCV mono- or HIV/HCV coinfection. As a control
group to control for use of cocaine, opioid and social
practices connected with drug use, we studied IDU
with similar injecting risk behavior that where mul-
tiple exposed but uninfected (MEU) from the
Amsterdam Cohort Studies (ACS) among drug users,
at two time-points during follow-up >15 years apart.
To address the severity of immune senescence param-
eters, we compared these between the specific IDU
groups and healthy individuals.
Results
Study population
We included 23 HIV/HCV coinfected, 21 HCV in-
fected and 8 MEU DU (Table 1) who all injected
Table 1 Baseline and follow-up characteristics of the study population
HD# MEU HCV HIV/HCV P-value
Number 22 8 21 23
General characteristics
Gender, n male (%) * 7 (87.5) 15 (71.4) 14 (60.9) 0.36
Western ethnicity, n (%) * 8 (100.0) 21 (100.0) 19 (82.6) 0.13
Ever injected drugs, n (%) * 8 (100.0) 21 (100.0) 23 (100.0) 1.00
Years of injecting (IQR) * 6.7 (6.1–13.6) 13.4 (5.4–19.6) 9.0 (6.4–14.6) 0.20
Baseline (T = 1)
Age, median (IQR) 36.4 (31.5–40.1) 32.8 (28.7–35.2) 34.4 (30.7–37.5) 35.2 (32.6–39.8) 0.30
Sample since study entry * 12.7 (0–47.6) 12.6 (1.7–31.7) 14.7 (0–25.8) 0.98
(months), median (IQR)
Year of sample, * 1992 (1989–1994) 1992 (1990–1994) 1991 (1989–1993) 0.43
median (IQR)
Injecting past 6 months(%) * 1 (12.5) 14 (66.7) 16 (73.9) 0.07
CD 4 cell counts 106 cells/L, * * * 590 (470–742) *
median (IQR)
cART, n (%) * * * 1 (4.5) *
Follow-up (T = 2)
Age, median (IQR) 52.7 (48.3–57.6) 51.7 (49.2–54.8) 51.7 (47.4–55.5) 50.4 (47.7–54.2) 0.97
Injecting past 6 months (%) * 1 (12.5) 4 (19.0) 4 (17.9) 0.92
CD 4 cell counts 106 cells/L, * * * 341 (233–663) *
median (IQR)
cART, n (%) * * * 20 (87.0) *
Years on cART, median (IQR) * * * 7.1 (2.1–10.7) *
cART combination anti-retroviral therapy, HCV Hepatitis C virus, HD Healthy donor, IQR Interquartile range, MEU Multiple exposed but uninfected with HCV or HIV
#HD at T = 1 and T = 2 are not the same individuals; * Data unavailable
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drugs for at least 2 years. The number of years of
injecting risk behavior was comparable between
groups, although MEU IDU reported less injecting in
the past 6 months prior to the baseline time point
(p = 0.07). At baseline, 1 out of 23 (4.5 %) HIV/HCV
IDU was on combination antiretroviral therapy
(cART) and this number increased to 20 out of 23
(87.0 %) at follow-up. The remaining three HIV/
HCV cases never received cART. For those who
received cART the median time since start cART
was 7.1 years (IQR 2.1–10.7). Median nadir CD4
count was 130 cells/mm3 (IQR 90–210).
Flowcytometric analyses of telomere length
Using flow-FISH, telomere length can be measured in
distinct cell populations without prior cell sorts [26].
Here we extended the flow-FISH protocol [27, 28] to a 5
color- flow-FISH (incorporating the phenotypic markers
CD3, CD8, CD27 and CD57) enabling us to investigate
CD4 and CD8 phenotypic T cell subsets in one sample.
The assay has been shown to be sensitive enough to
detect significant decreases in telomere length [28].
During ageing the relative telomere length (RTL)
decreases, as shown in Fig. 1a in CD8+ T cells over a




Fig. 1 Flowcytometric analysis of telomere length within T-cell subsets. a Representative histograms of CD8+ telomere length (blue) and calf
thymocytes (green) at the baseline timepoint (t = 1) and a follow-up timepoint more than 15 years later (t = 2). b Telomere length analysis (or
relative Telomere lengths) within T-cell subsets defined by CD27 and CD57-expression (left panel) as CD27 + CD57- (red), CD27-CD57- (green) and
CD27-CD57+ (purple). c Differences in relative telomere length (RTL) in healthy donors between immature (CD27 + CD57-), mature (CD27-CD57-)
and mature differentiated (CD27-CD57+) T cells stratified for CD4 (left panel) and CD8 T cells (right panel). The black lines represent median values.
Statistical analyses were performed using Kruskal-Wallis and post hoc Mann-Whitney U test, a two sided p-value <0.05 was considered
statistically significant
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defining immature (CD27+CD57-), mature (CD27-CD57-
) and mature differentiated (CD27-CD57+) phenotypes
[29, 30] (Fig. 1b), we were also able to show differences
in telomere length between these subsets (Fig. 1c). In
both CD4+ and CD8+ T cells, immature cells had signifi-
cantly longer RTL compared to mature and mature
differentiated cells (p < 0.001). Shortened telomeres have
been associated with CD57 expression on the surface of
T-cells [31]. Here we show that loss of CD27 expression
is already associated with reduced RTL in CD4+ and
CD8+ T cells. Mature and mature differentiated cells
have similar RTL, indicating that they have undergone
comparable rounds of proliferation (Fig. 1c).
Telomere length decreases over time in CD4+ and CD8+ T
cells and is mostly affected by HIV/HCV coinfection
We investigated whether there was a decrease in RTL
among CD4+ and CD8+ T cells over time (Fig. 2a). The
RTL of CD4+ T cells decreased significantly over time in
all IDU groups (p ≤ 0.012). An impact at baseline of
HCV monoinfection and HIV/HCV coinfection was
observed among the RTL in CD4+ T cells compared to
healthy donors (p = 0.008 and p = 0.002 respectively).
Among CD8+ T cells the RTL also decreased in all IDU
groups (p ≤ 0.017). The median RTL of CD8+ T cells
from HIV/HCV coinfected IDU at baseline was signifi-
cantly lower than in healthy donors (p = 0.0015) and
comparable to the median RTL of healthy donors, HCV
and MEU at follow-up (T = 2). In a sensitivity analysis,
using a linear regression model with age included as a fixed
variable, we demonstrated that the observed difference as
mentioned above were independent of age (Additional
file 1: Table S1). To analyse the decline in RTL per
individual, the 10 year RTL decline was calculated.
With increasing age, the RTL decline rate did not statisti-
cally differ between the study groups (Fig. 2b). Taken
together, these results suggest The effect of these infec-
tions occurred before the first time point of the study of
HIV/HCV coinfection on immune senescence.
Lower telomere lengths in immature T cells in HIV/HCV
coinfected IDU coincides with increased numbers of
differentiated cells
Persistent antigenic stimulation leads to linear differenti-
ation of naïve cells losing CD27 [32, 33] and gradually
gaining CD57 [30], resulting in a decreased capacity to
proliferate [34]. Therefore long-term effects of persistent
antigenic stimulation could be reflected in the percentage
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Fig. 2 Telomere length decreases over time in CD4+ and CD8+ T cells. a RTL of peripheral CD4 T cells (left panel) and CD8 T cells (right panel)
over time of: healthy donors (HD); multiple exposed uninfected (MEU) injecting drug users (IDU); HCV monoinfected IDU and HIV/HCV coinfected
DU. RTL was measured in the first available sample since study entry (t = 1) and the most recent sample (t = 2) of MEU, HCV monoinfected and
HIV/HCV coinfected DU. HD at time point 1 and 2 are not the same individuals. The median time interval for all groups between time point 1
and 2 was 16.9 years. Medians are depicted in the scatterplots. Wilcoxon-signed rank test was used for comparison within groups with the same
individuals (MEU, HCV and HIV/HCV). Kruskall-Wallis test were used to compare between groups followed by post hoc Mann-Withney U tests.
b Median levels of RTL decrease over time calculated per individual per 10 years for CD4 T cells (left panel) and CD8 T cells (right panel)
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of immature, mature and mature differentiated T-cell
subsets. As shown in Fig. 3a the proportion of immature
CD4+ and CD8+ T cells was significantly lower among
HIV/HCV coinfected IDU than healthy donors at both
baseline and follow-upt (p < 0.01) (Fig. 3c) fitting with the
lower telomere lengths in this patient group. However, we
did not observe a significant increase in the percentage of
differentiation over time within each of the study groups,
indicating that loss of telomere length over time is not
simply due to increased T-cell differentiation. Even more,
the RTL significantly decreased over time in all T-cell
subsets for all IDU groups (≤0.027, Fig. 3b and c). In
addition, in immature CD8+ T cells, the RTL in HIV/HCV
infected IDU was significantly lower compared to healthy
donors (p = 0.015). The CD27+CD57- immature CD4+ T
cells from young IDU with HCV or HIV/HCV also had a
lower RTL than healthy donors (p = 0.056 and p < 0.001
respectively). Thus, the decrease in telomere length over
time does not seem to be due to enhanced differentiation
of T cells, but affects all T-cell subsets.
Increased levels of activation and exhaustion in
peripheral T cells of HCV monoinfected and HIV/HCV
coinfected DU
To investigate whether the observed decrease in RTL
over time could be due to enhanced immune activation,
we analyzed the expression of HLA-DR and CD38 on T
cells. IDU with HIV/HCV coinfection had a significantly
higher frequency of CD4+ and CD8+ T-cell activation
(HLADR+CD38+) compared to healthy donors at both
baseline and follow-up (p < 0.004, Fig. 4). IDU with HCV
monoinfection had higher levels of CD8+ T cell activa-
tion at baseline compared to healthy donors (p < 0.001),
but this effect diminished over time. The level of CD4+
and CD8+ T cell activation declined over time in HIV/
HCV infected DU, but was still higher than in healthy
donors (p < 0.001). The expression of activation markers
was also significantly higher in HCV and HIV/HCV
infected IDU compared to MEU DU. Interestingly,
young MEU IDU were comparable to young healthy
donors with respect to immune activation, which
suggests there was no impact of drug use or social
practices on immune activation. However, the levels of
CD38 and HLA-DR among MEU IDU remained stable
over time, suggesting that MEU IDU may actively
suppress immune activation.
Persistent antigen exposure does not only lead to a
rapid turnover and telomere erosion but can also lead to
a subset of T cells that become functionally exhausted.
To investigate whether T-cell exhaustion is upregulated
by HIV and/or HCV we evaluated programmed death
factor 1 (PD-1) expression levels, shown to be marker of
exhaustion in chronic viral diseases but increasingly also
considered as activation marker after acute infection (to
control T-cell activity). At baseline both CD4+ and CD8+
T cells of HIV/HCV infected IDU expressed higher
levels of PD-1 than healthy donors. Over time, the CD8
PD-1 expression of HIV/HCV infected IDU declined
significantly (p = 0.014) to a level comparable to healthy
donors, most likely due to cART. Among HCV monoin-
fected IDU the expression of PD-1 in CD4+ T cells was
higher compared to healthy donors (p = 0.023). Even
though PD-1 expression in these cells significantly
increased over time (p = 0.005) the expression level was
comparable to older healthy donors, MEU and HIV/
HCV coinfected DU. Thus HIV/HCV coinfection leads




Study subjects were recruited from the ACS among DU,
an open, prospective cohort study to investigate the
prevalence, incidence, and risk factors of HIV infections
and other blood-borne diseases [35]. Enrollment is
voluntary, anonymous, and written informed consent is
obtained from each participant at the intake visit. The
medical ethics committee of the Academic Medical
Center approved this observational study. Blood is
drawn each visit for laboratory testing and storage of
peripheral blood mononuclear cells (PBMC) and serum.
HIV testing and HCV testing have been described before
[36]. In short, all participants were prospectively tested
for HIV antibodies and were confirmed by Western blot.
Chronic HCV infection was defined by the presence of
positive anti-HCV tests and the presence of HCV RNA
at multiple time-points during follow up, without
evidence for spontaneous clearance of HCV. None of
HCV-infected participants received HCV-treatment.
For this study we included three groups of DU,
namely: IDU who had an HIV/HCV coinfection (n = 23),
IDU who had a chronic HCV infection (n = 21) and as a
control for a drug using career IDU who were multiple
exposed but uninfected (MEU) (n = 8) (Table 1). Subjects
were included if they had an injecting drug use career
greater than 2 years, were aged between 43 and
60 years and had PBMCs available. In addition to
these follow-up samples we also included the first
available PBMCs sample since study entry in the ACS
for each subject. Unfortunately we were unable to in-
clude healthy donors with stored PBMC over the
same time period. Therefore, to compare the study
groups to healthy donors we recruited 2 groups of
anonymous healthy donors from the blood bank, one
aged between 43–60 years and one aged between 23–
43 years, in order to match the ages of our study
groups. In order to donate blood, voluntary participat-
ing individuals are tested for HIV, HBV, HCV and
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Fig. 3 (See legend on next page.)
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HEV. The blood bank actively screens for IDU and
men who have sex with men or a history of IDU or
men who have sex with men. These individuals were
excluded from blood donation.
PBMC storage
From all study participants, PBMCs were isolated from
heparinized blood using a Ficoll-Hypaque density
gradient centrifugation and cryopreserved using a
computerized freezing system in liquid nitrogen
within 24 h of collection.
Flow cytometric analyses
Stored PBMCs were rapidly thawed and 1*106 cells were
stained in PBS with 0.5 % bovine serum albumin (BSA)
and 0.1 % sodium azide using combinations of the follow-
ing antibodies: CD4 Pacific Blue, CD3 AlexaFluor700,
HLA-DR PerCP (Biolegend), CD8 Horizon V500, CD27
APC-eFluor780 (eBioscience), CD38 PE (Caltag) and PD-
1 PerCP-Cy5.5. Cells were incubated with the antibodies
for 20 min at 4 °C. After washing with PBS/0.5 % BSA,
cells were fixed with Cellfix (BD) and directly analyzed by
flow cytometry. For each sample a minimum of 100,000
(See figure on previous page.)
Fig. 3 No enhanced T-cell differentiation in time and lower relative telomere lengths (RTL) in immature CD4+ and CD8+ T cells. a Pie charts of
normalised median frequencies of immature (blue), mature (green) and mature differentiated (red) CD4+ (left panels) and CD8+ T cells (right
panels). Frequencies of immature cells were compared with HD for CD4+ and CD8+ T cells for time-point 1 and for time-point 2. P-values were
calculated using the Mann- Whitney U test. *p < 0.05; **p < 0.01; *** < 0.001. b Relative telomere length (RTL) of peripheral CD4 T cell subsets (b)
and CD8 T cell subsets (c) of: healthy donors (HD); multiple exposed uninfected (MEU) drug users (DU); HCV monoinfected IDU and HIV/HCV
coinfected DU. RTL was measured in the first available sample since study entry (t = 1) and the most recent sample (t = 2) of MEU, HCV
monoinfected and HIV/HCV coinfected DU. Subsets are depicted as follows: immature (CD27+CD57-), mature (CD27-CD57-) and mature differentiated
(CD27-CD57+). HD at time point 1 and 2 are not the same individuals. The median time interval for all groups between time point 1 and 2 was
16.9 years. Medians are depicted in the plots. Wilcoxon-signed rank test was used for comparison within groups with the same individuals (MEU, HCV
and HIV/HCV). Kruskall-Wallis test were used to compare between groups followed by post hoc Mann-Withney U tests
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Fig. 4 Levels of immune activation and exhaustion are increased in HCV/HIV coinfected injecting drug users (IDU). Percentages of HLA-DR/CD38
positive peripheral CD4+ T cells and CD8+ T cells (a) of: healthy donors (HD); MEU IDU; HCV monoinfected IDU and HIV/HCV coinfected DU. RTL
was measured in the first available sample since study entry (t = 2) and the most recent sample (t = 2) of MEU, HCV monoinfected and HIV/HCV
coinfected DU. b Median fluorescent intensity (MFI) of PD1 in peripheral CD4+ T cells and CD8+ T cells. Box and whisker plots show the median
and 10–90 percentiles. The Wilcoxon-signed rank test was used for comparison within groups with the same individuals (MEU, HCV and HIV/HCV).
Kruskall-Wallis test were used to compare between groups followed by post hoc Mann-Withney U tests
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cells were acquired using a LSRII FACS (BD) and data
were processed using FACSDiva 6.0 software (BD).
Flowcytometric analysis of telomere length in T
cell subsets
Telomere length of PBMCs was assessed using a five
color flow cytometry fluorescent in situ hybridization
(flow-FISH) protocol, adapted from Baerlocher et al.
[27] Here, telomeres are hybridized to an AlexaFluor488
labeled peptide nucleic acid (PNA) telomeric (C3TA2)3
probe and subsequently analyzed by flow cytometry. In
short, stored PBMCs were rapidly thawed and 2*106 cells
were stained with heat-stable fluorochrome-labeled anti-
bodies for CD3 Pacific Blue (eBioscience), CD8 V500
(BD), CD27 Alexa fluor 647 (BD) and CD57-biotin
(Biolegend), followed by streptavidin-Cy3 (Sigma). After
washing, the cells were fixed with bis(sulfosuccinimidyl)-
suberate (BS3, Pierce) for 30 min at 4 °C in the dark.
Cells were washed with PBS and incubated for 10 min
with an hybridization solution, with and without the
PNA probe and 15 min at 82 °C to denature the DNA.
After 1 h of hybridization at room temperature and in
the dark, cells were washed and analyzed immediately by
flow cytometry. Samples were gated on live, singlet CD3
+ T cells. Calf thymocytes were included in each experi-
ment as an internal control. The gating strategy is shown
in Additional file 2: Figure S1. Relative telomere length
(RTL) of each sample was calculated as the ratio
between the median fluorescent intensity (MFI) of the T
cell subset of interest with probe (minus the MFI with-
out probe) divided by the MFI of the calf thymocytes
with probe (minus the MFI without probe). All experi-
ments were performed in duplo and RTLs were averaged
per sample.
Statistical analyses
To test for statistical significance between groups we used
the Kruskall-Wallis test and if significant followed by
post-hoc Mann-Whitney U test. Comparisons within
groups (related samples) were made using the paired
Wilcoxon signed rank test, otherwise the Mann-Whitney
U test was used. A two sided p-value <0.05 was considered
statistically significant. To investigate whether the
decline in RTL could be confounded by age we per-
formed a sensitivity analysis using a linear regression
model with age as a fixed variable. All analyses were
performed using SPSS (version 20.0; SPSS Inc.) statis-
tical software. Graphs were made using Graphpad
(version 6.1; GraphPad Software, Inc.)
Discussion
In this longitudinal study we observed significantly
decreased telomere lengths among ageing HIV/HCV
coinfected IDU as compared to healthy donors. In the
period in which IDU had no access to cART, the impact
of HIV/HCV on telomere length was noticeable already
at the first timepoint in infection that we analysed, in
both the CD4 and CD8 T-cell compartment with signifi-
cantly reduced telomere lengths. During a period of
16 years we observed no increased decline of telomere
length between the study groups. These data suggest
that the lower telomere lengths were induced earlier in
infection. HCV monoinfected IDU had significantly
decreased telomere lengths in their CD4+ T cells, but
CD8+ T cells were not affected by increased telomere
erosion. Over time we observed no increase in the
percentage of differentiated cells in each study group,
but we did observe a continued decline of telomere
erosion. Therefore it is unlikely that T-cell differenti-
ation alone explains the continued telomere erosion.
Telomere decline could be explained by increased
peripheral levels of activation (HLA-DR+CD38+), mature
differentiated (CD27-CD57+) cells and exhaustion
(PD-1) in peripheral T cells of HCV monoinfected
and HIV/HCV coinfected IDU which indicates a state
of chronic immune activation.
As expected, we observed that telomere length de-
creased over time in all IDU groups. However this was
independent of viral coinfections (HCV or HIV/HCV).
Interestingly, at a relatively young age the telomere length
of predominantly CD8+ T cells, but also CD4+ T cells, was
markedly decreased in HIV/HCV coinfected individuals
and was comparable to more than 15 year older healthy
donors. As most HIV/HCV coinfected individuals were
cART naïve early during infection, the immune system
responds to HIV with high levels of activation and prolif-
eration rates [37]. Consequently HIV drives T cells to
increasingly differentiated phenotypes that are oligoclon-
ally expanded, less functional and more prone to apoptosis
[38]. We demonstrated that loss of telomere length is not
simply due to increased differentiation but mainly to
continued immune activation. Importantly, this study
demonstrates that the loss in telomere length mainly
occurred at the first time-point in infection that we
analysed and was not restored to the level of healthy
individuals with the initiation of cART. We could not rule
out that cART, via telomerase inhibition [39], negatively
affects telomere length. However a recent cross-sectional
study by Zanet et al. demonstrated no association between
low telomere length and cART exposure [40].
Here we found that HCV monoinfected IDU had
lower CD4+ T cell telomere lengths than healthy donors
at the first timepoint in infection that we analysed,
suggesting that HCV on its own may have an effect on
immune senescence. However, CD8+ T cell telomere
length was not affected. Unfortunately we had no
clinical outcomes to relate to, but a hospital-based
study found that, independent of age, decreased CD4+
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memory telomere length was associated with in-
creased liver fibrosis [41]. In addition, longer CD4+
and CD8+ T cell telomere lengths were both associ-
ated with a sustained virological response following
HCV treatment. We demonstrated that in HCV
monoinfected IDU the decreased telomere length in
CD4+ T cells occurred mainly in the immature T
cells. Although this population consists of both naïve
and central memory cells [42], reduced numbers of
CD4 naïve T cells and reduced recent thymic emi-
grants have been associated with HCV infection,
especially if fibrosis is present [43, 44]. This fits with
a model in which CD4+ T cells are continuously
activated during persistent HCV infection, especially
when the infection aggravates.. However, due to a lack
of samples we were unable to investigate the specific
responses of HIV/HCV coinfected DU.
The exact mechanisms through which HIV, HCV and
natural ageing collectively affect disease progression
remains to be resolved. Accumulating evidence points
towards a role for systemic immune senescence affecting
multiple organs/tissues. Data from a recent study among
IDU demonstrated that higher levels of interleukin 6, a
proinflammmatory cytokine, were independently associ-
ated with HCV monoinfection, HIV/HCV coinfection
and increasing age [45]. Decreased telomere length has
also been associated with atherosclerosis and cardiovas-
cular disease, and is likely to be correlated with interleu-
kin 6 levels [46].
Of interest, MEU IDU tended to have lower levels of
immune activation compared to healthy donors. This
special group of IDU has been shown to have detectable
HIV-specific [47] and HCV-specific T-cell responses
[48], indicating their exposure to both infections. The
notion of a naturally occurring resistance to certain viral
pathogens has major implications for T-cell vaccine
development. In a recent study though, robust activation
of natural killer cells, but not HCV-specific adaptive
immune responses, was associated with protection
against infection with HCV among MEU DU [49].
There were several limitations in this study. Due to
instability to heat we were unable to use CD45RA and
CCR7 as markers of memory and differentiation in our
assay. Interestingly, it did enable us to demonstrate that
loss of CD27 was significantly associated with telomere
loss in both CD4+ and CD8+ T cell, which occurred
before the upregulation of CD57 [31].
This study is limited by the unknown duration of HIV
and HCV infection. However, as the observed peak inci-
dence of HIV in Amsterdam occurred during the 80’s
[50] we assumed that our first time point of analysis was
close to the actual infection time point. For HCV the
observed peak prevalence also occurred during the 80’s.
We demonstrated that the reduction in telomere length
already occurred at the first time-point and that we did
not find any difference in the rate of telomere length
decline over a period of almost 17 years between MEU,
HCV monoinfected and HIV coinfected IDU. This
suggests that the telomere decline occurred earlier
during infection. But, we can not rule out that the HIV
or HCV infected IDU had lower telomere lengths pre-
acquisition of HIV or HCV. To prove our hypothesis it
would be of future interest to investigate telomere
decline in HIV and HCV seroconverters. Unfortunately
we had no access to bloodsamples of healthy donors
followed over time. Because we used different healthy
donors for the two time-points the decline in RTL could
be biased by inter-individual variations.
Conclusions
We found increased levels of immune senescence at the
first timepoint that we analysed in HCV mono- and
HIV/HCV coinfected DU. This suggests that HCV
mono-infection and HIV/HCV coinfection enhance T-cell
immune-senescence probably early during infection. As
both viruses have detrimental long-term effects on mor-
bidity and mortality, these data express the need for early
treatment, both for HCV and HIV infection.
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